Shared on 16 Dec 25

Fair value Decreased 0.0029%

LDOS: Strong Health And Civil Margins Will Support Future Premium Multiple

Analysts have raised their price target on Leidos Holdings to approximately $218.08 per share from about $218.08. This reflects slightly stronger expectations for revenue growth and sustained margins, supported by robust book to bill trends, a sizable near term pipeline, and upside earnings performance with higher profitability guidance into 2025.

Shared on 02 Dec 25

LDOS: Strong Health And Civil Margins Will Support Continued Margin Upside

Leidos Holdings saw its average analyst price target rise from $210 to $230 as analysts highlighted robust Health & Civil margins, a strong contract pipeline, and increased profitability guidance following recent earnings results. Analyst Commentary Recent analyst reports have highlighted several factors influencing sentiment around Leidos Holdings following the latest earnings results and guidance updates.

Shared on 18 Nov 25

Fair value Increased 8.05%

LDOS: Near-Term Contract Pipeline Will Drive Continued Margin Upside

Leidos Holdings' analyst price target has increased from $201.83 to $218.08 per share, as analysts cite strong margins in Health and Civil segments, a robust $69 billion pipeline, and raised profitability guidance as driving factors for the upward revision. Analyst Commentary Recent analyst reports have highlighted several factors that shape both the bullish and cautious outlooks for Leidos Holdings following its stronger-than-expected earnings performance and revised guidance.

Shared on 02 Nov 25

Fair value Increased 1.68%

Leidos Holdings saw its analyst price target rise from approximately $198.50 to $201.83. Analysts cited the company’s ongoing momentum in health services, robust margins, and its positioning to benefit from expanding federal funding priorities.

Shared on 18 Oct 25

Fair value Increased 1.95%

The average analyst price target for Leidos Holdings was raised by approximately $4 to $198.50. Analysts highlighted improving healthcare margins, stronger execution in health and defense services, and the company's positioning to benefit from recent government funding priorities.

Shared on 04 Oct 25

Fair value Increased 1.07%

The analyst price target for Leidos Holdings has been increased by approximately $2 to $194.71, as analysts cite ongoing strength in healthcare margins, opportunities in defense solutions, and improved business execution as key factors supporting the higher valuation. Analyst Commentary Recent Street research updates reflect a generally positive outlook on Leidos Holdings, with multiple analysts raising their price targets and upgrading the stock in response to improved business execution and strong performance in key sectors.

Shared on 19 Sep 25

Fair value Increased 1.32%

Upward analyst revisions for Leidos Holdings reflect confidence in its strategic investments in health and border security, strong healthcare margins, and effective leadership, resulting in a modest price target increase from $190.15 to $192.66. Analyst Commentary Bullish analysts highlight Leidos' strategic investments in veteran health, border security, and autonomous maritime, positioning the company to benefit from new government funding priorities.

Shared on 04 Sep 25

Fair value Increased 1.85%

Analysts maintain a positive outlook on Leidos Holdings due to strong execution in Health Services, favorable positioning for government funding priorities, increased management confidence, and a strategic pivot toward higher-margin growth sectors, resulting in an unchanged $186.69 price target. Analyst Commentary Continued strength and solid execution within Leidos' Health Services business, contributing to improved outlook and confidence.

Shared on 07 May 25

Fair value Increased 4.12%

Shared on 30 Apr 25

Fair value Increased 5.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Decreased 1.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 0.51%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 2.83%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 1.68%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Decreased 1.25%

AnalystConsensusTarget has decreased future PE multiple from 19.4x to 16.9x.

LDOS: Federal Health And Security Spending Will Drive Steady Performance Ahead

LDOS: Strong Health And Civil Margins Will Support Future Premium Multiple

LDOS: Strong Health And Civil Margins Will Support Continued Margin Upside

LDOS: Near-Term Contract Pipeline Will Drive Continued Margin Upside

Shared on 02 Nov 25

Shared on 18 Oct 25

Shared on 04 Oct 25

Shared on 19 Sep 25

Shared on 04 Sep 25

Shared on 07 May 25

Shared on 30 Apr 25

Shared on 23 Apr 25

Shared on 16 Apr 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Shared on 26 Mar 25

Shared on 19 Mar 25

Shared on 10 Mar 25